Trading a GRAL straddle lets you take a pure volatility position on GRAIL Inc without committing to a direction. GRAIL Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate GRAL straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on GRAL profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when GRAIL Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the GRAL straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the GRAL straddle is the cleanest expression of that view. Our scanner prices every GRAL straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a GRAL straddle into a catalyst or short a GRAL straddle to harvest decay, the options straddle setups that matter are all in one place.
